Although most evident in the skin, the process of scarring, or fibrosis, occurs in all major
organs because of impaired epithelial self‐renewal. No current therapy exists for Idiopathic …

IPF (idiopathic pulmonary fibrosis) is a chronic progressive disease of unknown aetiology
without effective treatment. IPF is characterized by excessive collagen deposition within the …

Pathogenic fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), have some of
the worst prognoses and affect millions of people worldwide. With unclear etiology and …

Transforming growth factor (TGF)-1 has been demonstrated to be important in the
pathogenesis of animal models of pulmonary fibrosis and in human fibrotic lung diseases. 1 …

Idiopathic Pulmonary Fibrosis (IPF) is characterized by injury and loss of lung epithelial
cells, accumulation of fibroblasts/myofibroblasts and abnormal remodeling of the lung …

Pulmonary fibrosis is an irreversible accumulation of connective tissue in the interstitium of
the lung. The pathogenesis of pulmonary fibrosis is not well understood. Research on …

Transforming growth factor-β (TGF-β) is extensively involved in the development of fibrosis
in different organs. Overproduction or potentiation of its profibrotic effects leads to an …

Idiopathic pulmonary fibrosis (IPF) is a deadly disease, largely unresponsive to treatment
with corticosteroids and immunosuppressives. The aim of this randomized, prospective …

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive fibroblast and
myofibroblast proliferation, and extensive deposition of extracellular matrix (ECM). Fibroblast …

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterised by subpleural fibrosis
that progresses to involve all areas of the lung. The expression of transforming growth factor …